➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Harvard Business School
Boehringer Ingelheim

Last Updated: July 4, 2020

DrugPatentWatch Database Preview

Paragraph IV Challenges

Email this page to a colleague

» See Plans and Pricing

« Back to Dashboard

Tradename Dosage Generic Name NDA Submissiondate
BELVIQ TABLET;ORAL lorcaserin hydrochloride 022529 2020-06-27
TRIJARDY XR TABLET, EXTENDED RELEASE;ORAL empagliflozin; linagliptin; metformin hydrochloride 212614 2020-05-26
BRIVIACT SOLUTION;ORAL brivaracetam 205838 2020-05-12
BRIVIACT SOLUTION;INTRAVENOUS brivaracetam 205837 2020-05-12
PROCYSBI CAPSULE, DELAYED RELEASE;ORAL cysteamine bitartrate 203389 2020-05-11
GOCOVRI CAPSULE, EXTENDED RELEASE;ORAL amantadine hydrochloride 208944 2020-04-30
NUPLAZID TABLET;ORAL pimavanserin tartrate 207318 2020-04-29
>Tradename >Dosage >Generic Name >NDA >Submissiondate

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Johnson and Johnson
Harvard Business School

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.